Public health impact and cost-effectiveness of the adjuvanted RSVPreF3 vaccine for respiratory syncytial virus prevention among adults aged 50 years and older in Germany
Open Access
- 5 August 2025
- journal article
- Published by Taylor & Francis in Expert Review of Vaccines
- Vol. 24 (1) , 782-796
Abstract
Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract disease in older adults. Vaccination is effective against RSV disease and can reduce disease and economic burden. A static, multicohort Markov model was adapted to the German setting to estimate the public health impact and cost-effectiveness of adjuvanted RSVPreF3 vaccination strategies from a societal perspective in three target populations: 1) at increased risk (AIR) adults aged 50-59 years and all adults ≥60 years, 2) all adults aged ≥60 years, and 3) AIR adults aged 60-74 years and all adults ≥75 years. A cycle length of 1 month and a 5-year time horizon were adopted. Vaccine coverage was 75% in the base case. RSV vaccination is cost-effective versus no vaccination (<€50,000 willingness-to-pay threshold): incremental cost-effectiveness ratios were €19,789, €19,631, and €12,733 for strategies 1, 2 and 3, respectively; 1.6, 1.4, and 0.8 million outpatient visits and 192,402, 185,238, and 152,781 hospitalizations could be prevented with strategies 1, 2, and 3, respectively. Expanding RSV vaccination to a larger target population would prevent more RSV cases, though at a higher cost per case averted; all vaccination strategies would be deemed cost-effective in Germany.Keywords
Funding Information
- GlaxoSmithKline
This publication has 37 references indexed in Scilit:
- Costs and Complications of Respiratory Syncytial Virus and Acute Respiratory Infections in the Adult Population: Analysis of a German Claims DatabasePharmacoEconomics - Open, 2025
- Acute Cardiac Events in Hospitalized Older Adults With Respiratory Syncytial Virus InfectionJAMA Internal Medicine, 2024
- Estimated Incidence of Hospitalizations and Deaths Attributable to Respiratory Syncytial Virus Infections Among Adults in Germany Between 2015 and 2019Infectious Diseases and Therapy, 2024
- Public Health Impact of the Adjuvanted RSVPreF3 Vaccine for Respiratory Syncytial Virus Prevention Among Older Adults in the United StatesInfectious Diseases and Therapy, 2024
- RSV vaccination strategies for high-risk patients 2023: a collaborative position paper by leading German medical societies and organizationsInfection, 2023
- 10 Years of AMNOG: What is the Willingness-to-Pay for Pharmaceuticals in Germany?Applied Health Economics and Health Policy, 2023
- Adjusting for Case Under-Ascertainment in Estimating RSV Hospitalisation Burden of Older Adults in High-Income Countries: a Systematic Review and Modelling StudyInfectious Diseases and Therapy, 2023
- Respiratory Syncytial Virus and Associations With Cardiovascular Disease in AdultsJACC, 2018
- Respiratory Syncytial Virus Infection in Older Adults: An Under-Recognized ProblemDrugs & Aging, 2015
- Self-Reported Population Health: An International Perspective based on EQ-5D2014